

Table 2: Incidence comparison with Canadian monograph

<b>Toxicity</b>	<b>VPA</b>		<b>CBZ</b>	
	<b>Our study</b>	<b>Monograph</b>	<b>Our study</b>	<b>Monograph</b>
<b>Neutropenia</b>	<b>9%</b>	< 1%	10%	10-20%
<b>Thrombocytopenia</b>	8%	1-27%	2%	1-10%
<b>Anemia</b>	<b>3%</b>	< 1%	<b>4%</b>	< 0.01%
<b>Elevated liver enzymes</b>	4%	1-5%	0	0.01-0.1
<b>Hyperammonemia</b>	<b>26%</b>	< 1%	-	-
<b>Hyponatremia</b>	-	-	0	<b>10-15%</b>
VPA: valproic acid; CBZ: carbamazepine; -: not evaluated.				